Expects to Receive an Additional Distribution of Approximately $36 Million Related to Takeda’s Upfront Payment in Second Quarter of 2023, for a Total Distribution of Approximately $147.3 Million NEW YORK --(BUSINESS WIRE)--Feb. 14, 2023-- Schrödinger Inc.
NEW YORK --(BUSINESS WIRE)--Feb. 13, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, will report its fourth quarter and full-year 2022 financial results on Tuesday, February 28, 2023 , after the
NEW YORK --(BUSINESS WIRE)--Jan. 31, 2023-- Schrödinger (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that management will participate in the SVB Securities Global Biopharma Conference and will give a
NEW YORK --(BUSINESS WIRE)--Jan. 20, 2023-- Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today reported that on January 16, 2023 , the company granted (i) non-statutory stock options to purchase an
New Target Added to Ongoing Collaboration with Bristol Myers Squibb Unveils LRRK2 Inhibitor Program Targeting Neurodegenerative Diseases New Collaboration and Software Agreement with Otsuka Pharmaceutical Co., Ltd. NEW YORK --(BUSINESS WIRE)--Jan. 9, 2023-- Schrödinger , Inc.